Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Aleix Prat et al.|New England Journal of Medicine|2022Cited by 2.5k
Protein expression patterns of cell cycle regulators in operable breast cancerFlora Zagouri, George Fountzilas|PLoS ONE|2017Cited by 43
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, G. Koumakis, Georgia-Angeliki Koliou et al.|ESMO Open|2020Cited by 38
Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-associated Breast Cancer TumorigenesisAnastasios Kyriazoglou, Flora Zagouri|In Vivo|2022Cited by 1